| 2003 | A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine |
| 2023 | Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2009 | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2021 | Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis | NEW ENGLAND JOURNAL OF MEDICINE |
| 2012 | Delamanid for multidrug-resistant pulmonary tuberculosis
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2010 | Dietary Therapy in Hypertension | NEW ENGLAND JOURNAL OF MEDICINE |
| 2017 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2021 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2017 | Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2012 | Porcelain aorta | NEW ENGLAND JOURNAL OF MEDICINE |
| 2013 | Riociguat for Pulmonary Hypertension
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2019 | Rivaroxaban in Patients With Heart Failure | NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2008 | Stents versus coronary-artery bypass grafting for left main coronary artery disease
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEW ENGLAND JOURNAL OF MEDICINE |
| 2007 | The Failing Heart | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
| NEW ENGLAND JOURNAL OF MEDICINE |
| 2020 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2022 | Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2015 | Trial of everolimus-eluting stents or bypass surgery for coronary disease | NEW ENGLAND JOURNAL OF MEDICINE |
| 2009 | Uric acid and cardiovascular risk. | NEW ENGLAND JOURNAL OF MEDICINE |
